Tiny DNA Insert in a Super-Enhancer Fine-Tunes Two Cancer Genes in Breast Tumors

A single stretch of inserted DNA, sitting inside one of the most active regulatory regions of the human genome, may help determine how aggressively breast cancer cells defend themselves against the immune system and against starvation. That is the central finding of a new study published in Cellular and Molecular Life Sciences, in which researchers at the University of California, San Francisco, together with collaborators in Chile and at Stanford University, dissected a genomic variant lodged within a super-enhancer that controls two cancer-promoting genes, LINC00636 and CD47. The work adds a striking example of how inherited differences in the non-coding genome, the vast majority of our DNA that does not encode proteins, can shape the behavior of tumor cells.

Super-enhancers are unusually large clusters of regulatory DNA sequences bound by high concentrations of transcription factors and co-activators. Unlike ordinary enhancers, which may boost the expression of a single nearby gene, super-enhancers often orchestrate entire cellular identity programs, and in cancer they are frequently hijacked to drive tumor-promoting gene networks. Because these regions are highly accessible, meaning the chromatin there is open and biochemically active, they are prime candidates for studying how genetic variation influences cancer risk and progression. Yet, as the authors of the new study note, the consequences of genomic variants within super-enhancers have remained poorly understood.

The team focused on a regulatory element they describe as bifunctional: a single super-enhancer that simultaneously controls the expression of two genes with very different biochemical outputs. One is LINC00636, a long non-coding RNA, a transcript that is copied from the genome but is not translated into a protein. The other is CD47, a well-known cell-surface protein often called a do-not-eat-me signal because it protects cells from being engulfed by immune cells called macrophages. CD47 is overexpressed in many cancers and has been a major target of experimental immunotherapies. The finding that one super-enhancer governs both a long non-coding RNA and a key immune-evasion molecule immediately suggested a mechanism by which a single DNA change could have layered effects on tumor biology.

Within this super-enhancer, the researchers identified a common germline insertion-deletion variant, or InDel, meaning that some people carry an extra segment of DNA inserted at this position while others do not. Germline variants are inherited and present in every cell of the body, in contrast to the somatic mutations that accumulate during tumor development. The team found that the insertion allele was associated with reduced chromatin accessibility at the super-enhancer locus. In practical terms, when the extra DNA segment is present, the regulatory region appears to be less open, and its activity is dialed down. Chromatin accessibility is a critical variable in gene regulation: open chromatin allows transcription factors and co-activators to bind, while closed chromatin locks them out.

To test whether this correlation reflected a causal relationship, the scientists used gene-targeting techniques to delete the insertion from breast cancer cells grown in the laboratory. The results were unambiguous. Removing the insertion increased chromatin accessibility at the super-enhancer, and this was followed by upregulation of both LINC00636 and CD47. In other words, the insertion acts as a kind of molecular brake on the super-enhancer, and removing the brake lets the two cancer-promoting genes run at higher levels. This experimental design, comparing otherwise identical cells that differ only at the InDel, allowed the researchers to isolate the effect of the variant from the thousands of other genetic differences that normally exist between individuals.

The downstream consequences of deleting the insertion revealed two distinct tumor-promoting programs. The first was mediated by CD47. With more CD47 on their surfaces, the engineered breast cancer cells showed enhanced resistance to apoptosis triggered by nutrient deprivation, the programmed self-destruction that cells normally undergo when starved of essential supplies. Tumors frequently face harsh metabolic conditions as they outgrow their blood supply, and the ability to survive nutrient stress is a recognized hallmark of aggressive cancer. The study’s data indicate that a common inherited variant in a super-enhancer can influence this survival trait through its effect on CD47 expression.

The second program was driven by elevated LINC00636. When the long non-coding RNA was increased, the cells showed activation of senescence, a state in which cells stop dividing but remain metabolically active and often secrete inflammatory signals. Senescence has a complicated relationship with cancer: it can suppress tumor growth directly, but senescent cells in the tumor microenvironment can also promote malignancy through the molecules they release. The authors report that this study establishes a previously unrecognized role for LINC00636 in senescence and breast cancer biology, making the long non-coding RNA a newly identified player in the disease rather than a genomic bystander.

The variant also appeared to reshape the immune landscape around tumor cells. Cells lacking the insertion, and therefore expressing higher levels of CD47, showed reduced infiltration by CD80-positive pro-inflammatory macrophages, the immune cells that help mount an attack against tumors. This observation connects the InDel to the tumor microenvironment, the ecosystem of immune and stromal cells that surrounds a cancer. A single inherited DNA change, by modulating a do-not-eat-me signal, may therefore influence not only how tumor cells behave in isolation but also how the immune system perceives and responds to them.

Taken together, the authors conclude that the insertion allele appears to have a protective role, since its presence dampens the activity of a super-enhancer driving cancer-promoting features. The findings carry several broader implications. For one, they demonstrate that common germline variation within super-enhancers can fine-tune regulatory output in ways that matter for cancer biology, extending the search for functional variants well beyond protein-coding regions and even beyond ordinary promoters and enhancers. For another, the bifunctional nature of the super-enhancer means that a single variant simultaneously influences an immune-evasion gene, a stress-resistance pathway, a senescence program, and immune-cell infiltration, illustrating how compact and interconnected the architecture of cancer gene regulation can be.

The study, which was funded in part by the NIH National Cancer Institute, the California Breast Cancer Research Program, and the Breast Cancer Research Foundation-AACR Career Development Awards, was published as an open-access article and is citable under the DOI 10.1007/s00018-026-06456-y. While the work was performed primarily in cell models and will need to be extended to patient cohorts to determine whether the insertion allele correlates with clinical outcomes, it provides a concrete mechanistic framework for a question that has long hovered over cancer genomics: what do the inherited variants in our non-coding DNA actually do? In this case, the answer is that a small insertion in a super-enhancer can quietly set the volume of two cancer genes at once, with consequences that ripple from chromatin structure all the way to the immune cells surrounding a tumor.

Subject of Research: A germline InDel variant within a bifunctional super-enhancer regulating LINC00636 and CD47 expression in breast cancer

Article Title: An InDel genomic variant within a bifunctional super-enhancer for LINC00636 and CD47 regulation in breast cancer

Article References: Di Benedetto, C., Tsark, A., Acenas, D., Thach, A., Singhal, A., Opazo-Mellado, V., Lemus, A. R., Zeini, M. E., Zhang, H., Park, C., Velozo, H. G., Weissmann, I., & Betancur, P. (2026). An InDel genomic variant within a bifunctional super-enhancer for LINC00636 and CD47 regulation in breast cancer. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06456-y

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06456-y

Keywords: super-enhancer, InDel variant, LINC00636, CD47, breast cancer, chromatin accessibility, long non-coding RNA, senescence, macrophages, gene regulation, cancer genomics, tumor microenvironment